Search

Your search keyword '"Chen, Andy I."' showing total 245 results

Search Constraints

Start Over You searched for: Author "Chen, Andy I." Remove constraint Author: "Chen, Andy I."
245 results on '"Chen, Andy I."'

Search Results

3. Durable response after tisagenlecleucel in adults with relapsed/refractory follicular lymphoma: ELARA trial update

5. Identifying an optimal fludarabine exposure for improved outcomes after axi-cel therapy for aggressive B-cell non-Hodgkin lymphoma

8. Impact of late immune effector cell associated hematotoxicity (ICAHT) and prolonged neutropenia after CAR-T therapy on infection and survival outcomes.

9. Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial

10. Outcomes of patients with secondary central nervous system lymphoma treated with chimeric antigen receptor T‐cell therapy: A CIBMTR analysis.

11. CAR T-Cell Immunotherapy in Minority Patients with Lymphoma

13. Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS)

14. Clinical Outcomes of Patients with Relapsed/Refractory Follicular Lymphoma Treated with Tisagenlecleucel: Phase 2 Elara 3-Year Follow-up

15. Defining the Optimal Post-CART Monitoring Period in Recipients of Axicabtagene Ciloleucel, Tisagenlecleucel, and Lisocabtagene Maraleucel: A Cell Therapy Consortium Study

16. Autologous Transplantation in Follicular Lymphoma with Early Therapy Failure: A National LymphoCare Study and Center for International Blood and Marrow Transplant Research Analysis

17. Outcomes of Medicare-age eligible NHL patients receiving RIC allogeneic transplantation: a CIBMTR analysis

18. A phase II trial of netupitant/palonosetron for prevention of chemotherapy-induced nausea/vomiting in patients receiving BEAM prior to hematopoietic cell transplantation.

19. Identifying an Optimal Fludarabine Exposure for Improved Outcomes after CD19 CAR T cell therapy for Aggressive B-NHL

20. Efficacy of Pharmacokinetics-Directed Busulfan, Cyclophosphamide, and Etoposide Conditioning and Autologous Stem Cell Transplantation for Lymphoma: Comparison of a Multicenter Phase II Study and CIBMTR Outcomes

22. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial

23. sj-docx-1-opp-10.1177_10781552231173863 - Supplemental material for A phase II trial of netupitant/palonosetron for prevention of chemotherapy-induced nausea/vomiting in patients receiving BEAM prior to hematopoietic cell transplantation

24. Chimeric Antigen Receptor T-Cell Therapy Yields Similar Outcomes in Patients with and without Cytokine Release Syndrome

25. Assessment of Healthcare Resource Utilization and Hospitalization Costs in Patients With Relapsed or Refractory Follicular Lymphoma Undergoing CAR-T Cell Therapy With Tisagenlecleucel: Results From the ELARA Study

27. Early Failure of Frontline Rituximab-Containing Chemo-immunotherapy in Diffuse Large B Cell Lymphoma Does Not Predict Futility of Autologous Hematopoietic Cell Transplantation

30. IBCL-271 Clinical Outcomes of Patients With Relapsed/Refractory Follicular Lymphoma (R/R FL) Treated With Tisagenlecleucel: Phase 2 ELARA 3-Year Follow-Up

31. Clinical Outcomes of Patients With Relapsed/Refractory Follicular Lymphoma (R/R FL) Treated With Tisagenlecleucel: Phase 2 ELARA 3-Year Follow- Up

32. Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial

33. ICU Utilization during Primary Admissions for Patients Undergoing Cellular Therapies with Allogeneic, Autologous or CAR-T Therapies

34. Long-Term Outcomes after Hematopoietic Cell Transplant in Peripheral T-Cell Lymphoma – the Oregon Health and Science University Experience

35. Assessment of Healthcare Resource Utilization (HCRU) and Hospitalization Costs in Patients (pts) with Relapsed or Refractory (r/r) Follicular Lymphoma (FL) Undergoing CAR-T Cell Therapy with Tisagenlecleucel: Results from the Elara Study

36. Efficacy of Tisagenlecleucel in Adult Patients (Pts) with High Risk Relapsed/Refractory Follicular Lymphoma (r/r FL): Subgroup Analysis of the Phase 2 Elara Study

37. Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial

39. Safety and efficacy of polatuzumab vedotin + obinutuzumab for relapsed/refractory non‐Hodgkin lymphomas: A phase IB / II study

41. CD19 CAR T-cell product type independently impacts CRS and ICANS severity in patients with aggressive NHL.

44. Autologous haematopoietic cell transplantation for non-Hodgkin lymphoma with secondary CNS involvement

50. 420 - ICU Utilization during Primary Admissions for Patients Undergoing Cellular Therapies with Allogeneic, Autologous or CAR-T Therapies

Catalog

Books, media, physical & digital resources